The peptide reference, by the numbers.

Retatrutide vs Tirzepatide

Triple agonist versus dual agonist: what adding the glucagon receptor changes in the published data.

Semaglutide vs Tirzepatide

The most-compared pair in metabolic research, including the first direct head-to-head obesity trial.

Semaglutide vs Retatrutide

One receptor versus three: the established GLP-1 benchmark against the leading investigational triple agonist.

BPC-157 vs TB-500

The two most-discussed repair peptides: how their proposed mechanisms differ and how thin the human data is.

BPC-157 vs GHK-Cu

Injury-site repair research versus a copper tripeptide studied for collagen and skin remodelling.

Sermorelin vs Tesamorelin

Two GHRH analogs on the same pituitary receptor, with very different regulatory histories.